BTG (company)

Last updated
BTG Limited
Type Private limited company
Industry Healthcare
Founded1991 as British Technology Group Ltd.
Headquarters London, United Kingdom
Key people
Garry Watts (Chairman of the board), Louise Makin (CEO), Duncan Kennedy (CFO)
ProductsDevelopment, manufacturing and commercialisation of specialty pharmaceuticals and interventional medicine in the areas of critical care, cancer and varicose veins. BTG also has a revenue stream from royalty payments on partnered products.
Revenue £620.5 million (2018) [1]
Parent Boston Scientific
Website www.btgplc.com

BTG Limited is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The current name was adopted when the British Technology Group changed its name on 27 May 1998. [2] BTG was a constituent of the FTSE 250 Index until it was acquired by Boston Scientific in August 2019.

Contents

History

In 1948, the National Research Development Corporation was formed with the purpose of commercialising innovations that arose from public funded research. [3] This was complemented, in November 1975, by the establishment of the National Enterprise Board to implement the then-Government's policy of moving public sector industry into commercial private enterprise. [4]

These two organisations were merged by the Government in 1981 to form a new, non-statutory body called the British Technology Group. [5] It acted principally to license and commercialise the use of publicly funded developments. The Group was put onto a statutory footing in the British Technology Group Act 1991 [6] with HM Treasury initially being the only shareholder. Subsequently, in March 1992, Cinven arranged a management buy-out from the Government. The company later floated on the London Stock Exchange in 1995. [3] Three years later, on 27 May 1998, the Group adopted its present name. It now focuses its work on developing and commercialising medical innovations. [3]

Since acquiring the commercialisation rights to magnetic resonance imaging (MRI) (under a revenue share scheme) in 1983, BTG has come to license a large part of the world market in MRI, including licensees such as General Electric and Philips. [7]

BTG plc completed the acquisition of Protherics PLC in December 2008 and of Biocompatibles International plc in January 2011. [8] In May 2016 BTG plc acquired the Israeli company Galil Medical for US$110 million. [9] In September 2018, BTG plc acquired Novate Medical for up to $150 million. [10]

In late November 2018 Boston Scientific announced it would acquire BTG for $4.2 billion. [11] The transaction was due to complete in August 2019. [12]

Operations

BTG earns revenues from specialty pharmaceutical and interventional medicine product sales and on royalties from partnered products. [13] It trades as BTG International Inc. in the United States and as BTG International Ltd. in the United Kingdom. [14]

See also

Related Research Articles

BT Group plc is a British multinational telecommunications holding company headquartered in London, England. It has operations in around 180 countries and is the largest provider of fixed-line, broadband and mobile services in the UK, and also provides subscription television and IT services.

<span class="mw-page-title-main">GE HealthCare</span> American multinational medical technology company

GE HealthCare Technologies, Inc., doing business as GE HealthCare, is an American multinational medical technology company headquartered in Chicago, Illinois. It was spun-off from General Electric on January 4, 2023, with GE retaining 13.5%. As of 2017, it is a manufacturer and distributor of diagnostic imaging agents and radiopharmaceuticals for imaging modalities used in medical imaging procedures. It offers dyes used in magnetic-resonance-imaging procedures; manufactures medical diagnostic equipment, including CT image machines; MRI, XRAY; Ultrasound; Cath Labs; Mammogram; Nuclear Medicine Cameras; and develops Health technology for medical imaging and information technologies, medical diagnostics, patient monitoring systems, disease research, drug discovery, and biopharmaceutical manufacturing. It was incorporated in 1994 and operates in more than 100 countries.

<span class="mw-page-title-main">UCL Business</span> University technology-transfer company

UCL Business PLC is the technology-transfer company of University College London Hospital NHS Foundation Trust in London, England. Its head office is on Tottenham Court Road in the London Borough of Camden.

The National Enterprise Board (NEB) was a United Kingdom government body. It was set up in 1975 by the Labour government of Harold Wilson, to support the government's interventionist approach to industry. In 1981 the Conservative government of Margaret Thatcher, combined the NEB with the National Research Development Corporation (NRDC) to form the British Technology Group.

<span class="mw-page-title-main">Boston Scientific</span> U.S.-based medical device company

Boston Scientific Corporation ("BSC"), incorporated in Delaware, is a biomedical/biotechnology engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Boston Scientific is widely known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries. With the full acquisition of Cameron Health in June 2012, the company also became notable for offering a minimally invasive implantable cardioverter-defibrillator (ICD) which they call the EMBLEM subcutaneous implantable defibrillator (S-ICD).

Nordion Inc., a Sotera Health company, is a health science company that provides Cobalt-60 used for sterilization and treatment of disease (radiotherapy).

<span class="mw-page-title-main">Robert S. Langer</span> American scientist

Robert Samuel Langer Jr. FREng is an American biotechnologist, businessman, chemical engineer, chemist, and inventor. He is one of the twelve Institute Professors at the Massachusetts Institute of Technology.

<span class="mw-page-title-main">Celltech</span> Former British-based biotechnology firm

Celltech Group plc was a leading British-based biotechnology business based in Slough. It was listed on the London Stock Exchange and was a constituent of the FTSE 100 Index. Celltech was instrumental in changing the UK's system of technology transfer from research to business, and in creating the biotechnology industry.

Spectris plc is a supplier of precision instrumentation and controls. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

Biocompatibles International plc was a medical technology company in the field of drug-device combination products. It was acquired by BTG plc in 2010, which was, in turn, acquired by Boston Scientific in 2019.

<span class="mw-page-title-main">Oxford University Innovation</span>

Oxford University Innovation Limited (OUI) is a British technology transfer and consultancy company created to manage the research and development (R&D) of University spin-offs. OUI is a wholly owned subsidiary of the University of Oxford, and is located on Botley Road, Oxford, England. OUI was previously known as Isis Innovation (1988–2016) and Oxford University Research and Development Ltd (1987–1988).

<span class="mw-page-title-main">Elron Electronic Industries</span>

Elron Electronic Industries is an Israeli technology holding company based in Tel Aviv; since 1962 the company has been involved in setting up, funding and developing over 30 companies and is considered one of the foundation stones of the high-tech industry in Israel. The company's sectors of interest include clean technology, software, semiconductors, medical technology, telecommunications, defence and aerospace. Today, the combined annual revenues of the companies established by Elron are approximately $5 billion.

On 29 March 2010, the US District Court for the Southern District of New York found several of the patent claims on the BRCA1 and BRCA2 breast cancer genes held by Myriad Genetics to be invalid. The patents were initially issued on the basis that the genes were isolated and purified to a non-naturally occurring state, however the court found, amongst other things, that the purification was not markedly different from a product of nature and thus was not patentable. The ruling may have implications for holders of other gene patents and the patentability of other naturally occurring substances. It has the potential to directly affect the operation of the healthcare and medical research industries, particularly with regards to cancer treatment and prevention, and may alter the accessibility of such therapies to patients.

<span class="mw-page-title-main">LifeArc</span>

LifeArc is a British life science medical research charity. It was established in 2000 as MRC Technology to translate the work of UK Medical Research Council (MRC) research scientists.

<span class="mw-page-title-main">GW Pharmaceuticals</span>

GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Fusion IP plc was a UK-based listed company that capitalised on intellectual property extracted from four UK-based universities, three of which were part of the Russell Group of universities:

Eckhard U. Alt is a German scientist and physician known for his contributions in cardiology and research.

The Bill & Melinda Gates Medical Research Institute is a non-profit biotechnology organization founded with the aim of bringing technologies and strategies to bear on the main health problems of the poor in low-income countries. The Gates MRI was organized as a subsidiary of the Bill & Melinda Gates Foundation who funded it with a $273 million 4-year grant.

ICON plc is an Irish headquartered Nasdaq listed multinational healthcare intelligence and clinical research organisation that provides consulting, clinical development and commercialisation services for the pharmaceutical industry. As of June 2023, ICON had approximately 41,160 employees in 108 locations spread across 53 countries.

References

  1. "Preliminary Results 2018" (PDF). BTG. Retrieved 16 March 2019.
  2. "Companies House WebCheck". companieshouse.gov.uk. Retrieved 23 March 2015.
  3. 1 2 3 "Overview of BTG International's history". Archived from the original on 2006-08-26. Retrieved 2007-12-30.
  4. Elizabeth II (1975). Industry Act 1975 . HM Stationery Office. ISBN   0-10-546875-4.
  5. Abstract of Department of Trade and Industry report "Monitoring of British Technology Group"
  6. "British Technology Group Act 1991". Legislation.gov.uk. Retrieved 6 May 2016.
  7. "Case study of BTG's MRI licensing". Archived from the original on 2007-08-07. Retrieved 2007-12-30.
  8. "BTG's £177m deal to buy cancer treatment firm Biocompatibles International". The Evening Standard. Retrieved 23 March 2015.
  9. BTG acquires Galil Medical for $110m, Globes , May 5, 2016
  10. "BTG plc acquires Novate Medical Ltd".
  11. "Boston Scientific to Acquire U.K. Medical Device Company BTG for $4.2 Billion". Biospace. 20 November 2018. Retrieved 16 March 2019.
  12. "BTG shareholders OK $4B Boston Scientific buyout". Mass Device. 1 March 2019. Retrieved 16 August 2019.
  13. "Prostate cancer drug boosts BTG". FT. 5 October 2011. Retrieved 16 April 2017.
  14. "BTG plc - Contact Us". btgplc.com. Archived from the original on 4 April 2015. Retrieved 23 March 2015.